BDRX - Midatech Pharma Plc
4.35
-0.030 -0.690%
Share volume: 6,888
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.37%
PREVIOUS CLOSE
CHG
CHG%
$4.38
0.04
0.01%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.27%
1 Month
-2.25%
3 Months
-22.74%
6 Months
595.78%
1 Year
229.55%
2 Year
-98.31%
Key data
Stock price
$4.35
DAY RANGE
$4.19 - $4.40
52 WEEK RANGE
$0.23 - $10.89
52 WEEK CHANGE
$222.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Stephen A. Stamp
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: midatechpharma.com
Employees: 20
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Midatech Pharma plc focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. MTX114, an immuno-suppressant for topical application in psoriasis, MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder.
Recent news